Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ1 | P51787 | 2/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 8/20 | 0.46 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.45 |
| ▸ | ITGAV | P06756 | 3/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.43 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.43 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1381826 | 1.00 | KCNQ1 (0.49) | KCNQ1ITGB1ITGA5ITGA4LMNA | |
| SCHEMBL629871 | 0.93 | KCNQ1 (0.48) | KCNQ1ITGB1ITGA5ITGA4LMNA | |
| SCHEMBL1384421 | 0.93 | KCNQ1 (0.48) | KCNQ1ITGB1ITGA5ITGA4LMNA | |
| SCHEMBL630557 | 0.93 | ITGB1 (0.53) | KCNQ1ITGB1ITGA5ITGA4LMNA | |
| SCHEMBL630558 | 0.93 | ITGB1 (0.53) | KCNQ1ITGB1ITGA5ITGA4LMNA | |
| SCHEMBL1381634 | 0.90 | KCNQ1 (0.46) | KCNQ1ITGB1ITGA5ITGA4LMNA | |
| SCHEMBL629881 | 0.90 | KCNQ1 (0.46) | KCNQ1ITGB1ITGA5ITGA4LMNA | |
| SCHEMBL631137 | 0.89 | KCNQ1 (0.41) | KCNQ1ITGB1ITGA5ITGA4LMNA | |
| SCHEMBL1381179 | 0.89 | KCNQ1 (0.47) | KCNQ1ITGB1ITGA5ITGA4LMNA | |
| SCHEMBL8268315 | 0.88 | KCNQ1 (0.48) | KCNQ1ITGB1ITGA5ITGA4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778637-B1 | FKBP-binding composition and pharmaceutical use thereof | AVENTIS PHARMA INC (US) | 2012-02-22 | — | — | EP | claimed |
| JP-4812758-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| EP-1778637-B1 | FKBP-binding composition and pharmaceutical use thereof | AVENTIS PHARMA INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7777042-B2 | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7777042-B2 | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | FKBP1A, FKBP1B, FKBP3 | KCNQ1 4358/4885ITGB1 3840/4885ITGA5 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.